Literature DB >> 10373563

Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.

M T Abreu-Martin1, A Chari, A A Palladino, N A Craft, C L Sawyers.   

Abstract

Mitogen-activated protein (MAP) kinases phosphorylate the estrogen receptor and activate transcription from estrogen receptor-regulated genes. Here we examine potential interactions between the MAP kinase cascade and androgen receptor-mediated gene regulation. Specifically, we have studied the biological effects of mitogen-activated protein kinase kinase kinase 1 (MEKK1) expression in prostate cancer cells. Our findings demonstrate that expression of constitutively active MEKK1 induces apoptosis in androgen receptor-positive but not in androgen receptor-negative prostate cancer cells. Reconstitution of the androgen receptor signaling pathway in androgen receptor-negative prostate cancer cells restores MEKK1-induced apoptosis. MEKK1 also stimulates the transcriptional activity of the androgen receptor in the presence or absence of ligand, whereas a dominant negative mutant of MEKK1 impairs activation of the androgen receptor by androgen. These studies demonstrate an unanticipated link between MEKK1 and hormone receptor signaling and have implications for the molecular basis of hormone-independent prostate cancer growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373563      PMCID: PMC84357          DOI: 10.1128/MCB.19.7.5143

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression.

Authors:  M Faris; N Kokot; K Latinis; S Kasibhatla; D R Green; G A Koretzky; A Nel
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

2.  14-3-3 proteins interact with specific MEK kinases.

Authors:  G R Fanger; C Widmann; A C Porter; S Sather; G L Johnson; R R Vaillancourt
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

3.  Identification of domains of c-Jun mediating androgen receptor transactivation.

Authors:  S C Wise; L A Burmeister; X F Zhou; A Bubulya; J L Oberfield; M J Birrer; L Shemshedini
Journal:  Oncogene       Date:  1998-04-16       Impact factor: 9.867

4.  Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEKK1.

Authors:  J C Deak; J V Cross; M Lewis; Y Qian; L A Parrott; C W Distelhorst; D J Templeton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy.

Authors:  G S Prins; R J Sklarew; L P Pertschuk
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

Review 6.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.

Authors:  J Veldscholte; C A Berrevoets; C Ris-Stalpers; G G Kuiper; G Jenster; J Trapman; A O Brinkmann; E Mulder
Journal:  J Steroid Biochem Mol Biol       Date:  1992-03       Impact factor: 4.292

7.  Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals.

Authors:  C Widmann; S Gibson; G L Johnson
Journal:  J Biol Chem       Date:  1998-03-20       Impact factor: 5.157

8.  Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1.

Authors:  H Nakano; M Shindo; S Sakon; S Nishinaka; M Mihara; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance.

Authors:  M Marcelli; W D Tilley; C M Wilson; J E Griffin; J D Wilson; M J McPhaul
Journal:  Mol Endocrinol       Date:  1990-08

10.  Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.

Authors:  Y Shi; J M Glynn; L J Guilbert; T G Cotter; R P Bissonnette; D R Green
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

View more
  61 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

2.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

Review 3.  Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Authors:  Pushpendra Singh; Jimi Marin Alex; Felix Bast
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

4.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

5.  Suppression of miR-4735-3p in androgen receptor-expressing prostate cancer cells increases cell death during chemotherapy.

Authors:  Weidong Zhou; Shengsong Huang; Qiquan Jiang; Tao Yuan
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 6.  Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

Review 7.  Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.

Authors:  Vaqar Mustafa Adhami; Deeba Nadeem Syed; Naghma Khan; Hasan Mukhtar
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

8.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

9.  Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

10.  Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.

Authors:  Ayush Dagvadorj; Shyh-Han Tan; Zhiyong Liao; Luciane R Cavalli; Bassem R Haddad; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.